Cancer Therapy Promise Makes Roche the Darling of Drug Stocks
This article is for subscribers only.
Roche Holding AG is analysts’ favorite big pharmaceutical stock going into JPMorgan Chase & Co.’s annual health-care conference, where industry executives flock to hold court with top investors.
The world’s biggest maker of cancer drugs, based in Switzerland, won U.S. approval for two new medicines last quarter. Oncology is one of the fastest-growing therapy areas, accounting for about 20 percent of branded drug sales. Roche also expects approval this year for multiple sclerosis treatment ocrelizumab.